Skip to main content

Guidelines Updated for Unstable Angina/Non-ST Elevation Myocardial Infarction


CLINICAL CONTEXT

According to the current study by Jneid and colleagues, new evidence is available on the management of unstable angina. This report replaces the 2007 American College of Cardiology Foundation/American Heart Association (ACC/AHA) Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (UA/NSTEMI) that were updated by the 2011 guidelines.
This guideline was reviewed by 2 official reviewers each nominated by the ACCF and the AHA, as well as 1 or 2 reviewers each from the American College of Emergency Physicians; the Society for Cardiovascular Angiography and Interventions; and the Society of Thoracic Surgeons; and 29 individual content reviewers, including members of the ACCF Interventional Scientific Council. The recommendations in this focused update are considered current until they are superseded in another focused update or the full-text guideline is revised. Guidelines are official policy of both the ACCF and the AHA.

STUDY SYNOPSIS AND PERSPECTIVE

American cardiology societies have caught up with the European Society of Cardiology by issuing their second update to the UA/NSTEMI guidelines in 18 months, with the 2012 focused update replacing the 2011 guidelines [1]. The new recommendations include ticagrelor (Brilinta) as one of the options for antiplatelet therapy alongside prasugrel (Effient) andclopidogrel, bringing them in line with European guidance issued last September.
The European guidance, however, gave precedence to the new antiplatelets over clopidogrel, whereas the American update "places ticagrelor on an equal footing with the other two antiplatelets available--this is the main reason for the update," lead author Dr Hani Jneid (Baylor College of Medicine, Houston, TX), told heartwire . "Doctors now have a choice for second-line therapy after aspirin, depending on the patient's clinical scenario, physician preference, and cost," because the latter will come into play now that clopidogrel is available generically, he noted.
The US decision to recommend first prasugrel--in its 2011 update to the UA/NSTEMI guidelines--and now ticagrelor as equivalent antiplatelet therapy choices to clopidogrel after aspirin puts it somewhat at odds with the Europeans, who reserve clopidogrel use for those who cannot take the newer agents.
But Jneid says the Americans have their reasons for this differing stance. While it is "biologically plausible" to recommend ticagrelor and prasugrel in preference to clopidogrel--"because they are faster acting and more potent"--the cost-effectiveness of the new agents is not known, he says. Nor is it clear how the efficacy observed in pivotal clinical trials of these agents is going to translate into real-world benefit, he says, adding that issues such as bleeding with prasugrel and compliance with a twice-daily drug such as ticagrelor remain concerns.
Bulk of 2012 Update on How to Use Ticagrelor
The 2012 ACCF/AHA focused update for the management of UA/NSTEMI stresses that all patients at medium/high risk should receive dual antiplatelet therapy on admission, with aspirin being first-line, indefinite therapy.
The bulk of the update centers on how to use ticagrelor which--like prasugrel or clopidogrel--can be added to aspirin for up to 12 months (or longer, at the discretion of the treating clinician). Jneid notes it's important to remember that prasugrel can only be used in the cath lab in patients undergoing percutaneous coronary intervention (PCI), whereas ticagrelor, like clopidogrel, can be used in medically managed or PCI patients.
And he emphasizes that, in line with the FDA's black-box warning on ticagrelor, this new antiplatelet agent must only be administered with a "baby" dose of aspirin (81 mg in the US).
The 81-mg aspirin dose is also considered a reasonable option in preference to a higher maintenance dose of 325 mg in any acute coronary syndrome (ACS) patient following PCI, he adds, as this strategy is believed to result in equal efficacy and lower bleeding risk.
With regard to how long antiplatelet therapy should be stopped before planned cardiac surgery, the recommendation is five days for ticagrelor--the same as that advised for clopidogrel. For prasugrel, the guidance is to stop therapy seven days prior to surgery.
Jneid also highlights other important recommendations from the 2011 focused update carried over to 2012:
It is "reasonable" to proceed with cardiac catheterization and revascularization within 12–24 hours of admission in initially stable, very high-risk patients with ACS.
An invasive strategy is "reasonable" in patients with mild and moderate chronic kidney disease.
In those with diabetes hospitalized with ACS, insulin use should target glucose levels <180 mg/dL, a less-intensive reduction than previously recommended.
Platelet function or genotype testing for clopidogrel resistance are both considered "reasonable" if clinicians think the results will alter management, but it is acknowledged that "there is not much evidence to support these assays," says Jneid.
Committee Encourages Participation in Registries
Jneid observes that unstable angina and NSTEMI are "very common" conditions that carry a high risk of death and recurrent heart attacks, which is why "the AHA and ACCF constantly update their guidelines so that physicians can provide patients with the most appropriate, aggressive therapy with the goal of improving health and survival."
To this end, he notes that the writing panel encourages clinicians and hospitals to participate in quality-of-care registries designed to track and measure outcomes, complications, and adherence to evidence-based medicines.
Conflicts of interest for the writing committee are listed in the paper.
References
  1. Jneid H, Anderson JL, Wright SR, et al. 2012 ACCF/AHA focused update on the guideline for the management of patients with unstable angina/non-ST elevation myocardial infarction (Updating the 2007 guideline and replacing the 2011 focused update): A report of the ACCF/AHA. Circulation 2012;DOI: 10.1161/CIR0b013e3182566fleo. Available at:http://circ.ahajournals.org/.

Comments

  1. Darius8 May 2014 at 00:23

    I am a medical resident on cardiology and I also wrote a few words about unstable angina.

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Obama Renominates Tavenner to Be CMS Chief

President Barack Obama yesterday renominated Marilyn Tavenner, the acting administrator of the Centers for Medicare & Medicaid Services (CMS), to serve in that post without the caveat of "acting" attached to it. If the Senate approves her nomination, Tavenner will be the first confirmed, full-fledged CMS administrator since Mark McClellan, MD, PhD, stepped down from that position in October 2006, during the George W. Bush administration. Dr. McClellan's successors either were acting administrators or, in the case of Donald Berwick, MD, who was Tavenner's immediate predecessor, a recess appointment. As illustrated by Dr. Berwick's  CMS history , Senate confirmation can be tough to get when one party has enough votes to filibuster and otherwise stymie a nomination by an opposing party's president. That was the case when Obama nominated Dr. Berwick, whom Senate Republicans portrayed as an advocate of healthcare rationing, a characterization denied by t...
Post a Comment
Read more

Secondary Prevention: Clinical Approaches to Managing the Higher-Risk Patient with Heart Disease

INCIDENCE/PREVALENCE/BURDENS ASSOCIATED WITH CARDIOVASCULAR DISEASE (CVD) The prevention of an initial and recurrent cardiovascular event and other complications, such as diabetes and kidney failure [also known as end-stage renal disease (ESRD) or chronic kidney disease (CKD) stage 5] is an important goal in patients with a history of CVD. Each year, approximately 185,000 Americans suffer a recurrent stroke, approximately 470,000 will have a recurrent coronary attack, and an estimated 325,000 will suffer a recurrent myocardial infarction. [1]  Secondary prevention strategies offer the opportunity to prevent further complications and improve outcomes by early detection and management of common comorbidities. The burden on public health and the costs associated with chronic illnesses such as CVD, CKD, and diabetes remain high. An estimated 82.6 million American adults (1 in 3) have 1 or more types of CVD. [1]  Heart failure is the fastest-growing clinical cardiac disease ...
Post a Comment
Read more